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| INTRODUC TI ON
Atrial fibrillation (AF) is the most common cardiac arrhythmia, with an estimated prevalence of 0.56%-1.6% in Asian countries (China, Japan, Korea, and Singapore). 1, 2 AF is an independent risk factor for stroke (a nearly five-fold increase 3 ) and is associated with stroke death (a nearly three-fold increase 4 ), making the growing prevalence of AF a major healthcare concern. For decades, warfarin has been used for prevention of ischemic stroke in patients with AF. However, several new non-vitamin K oral anticoagulants (NOACs) are now available in many countries to alleviate the unmet need left by traditional anticoagulants, and are recommended for use in the latest guidelines in the United States, 5 Europe, 6 and Japan. 7 The randomized controlled trial ARISTOTLE showed that apixaban, an oral direct factor Xa inhibitor, was effective in preventing stroke and systemic embolism (SE) in patients with nonvalvular AF (NVAF). 8, 9 Apixaban received regulatory approval in Japan in 2012
for the prevention of ischemic stroke and SE in patients with NVAF.
To date, the real-world safety and effectiveness of apixaban in patients with NVAF have been assessed in retrospective claims database studies both outside of Japan [10] [11] [12] [13] and in Japan. 14 However, data are still limited in Japanese NVAF patients.
After introduction of NOACs into clinical practice, the proportion of NVAF patients now given NOACs has been increasing worldwide. 15, 16 In a certain proportion of these patients, warfarin was switched to NOACs and NOACs were switched to other NOACs. 16 However, reasons for the switch, as well as safety and effectiveness of the switch have not been elucidated thoroughly yet in clinical practice.
As required for a new medicine approved by the Ministry of Health, Labour and Welfare, safety and effectiveness information for the medicine should be provided in the setting of routine practice. Consequently, we conducted a postmarketing surveillance (PMS) study, STroke prevention ANticoagulant Drug Apixaban Realworld Data (STANDARD, ClinicalTrials.gov ID: NCT02007655), to assess the safety and effectiveness of apixaban in Japanese NVAF patients in routine clinical practice. Herein, we report baseline clinical characteristics and incidences of outcome events among all the study patients, as well as among the patient groups based on prior status of anticoagulation therapy.
| ME THODS

| Study design, study period, and sample size setting
This PMS study was conducted at 811 sites across Japan from
September 2013 (start of registration) until August 2016 (end of follow-up). On the basis of the incidence rate of major bleeding observed in the ARISTOTLE study, 8 a target sample size of 1000 and 1600 was set for patients receiving apixaban 2.5 and 5 mg twice daily (BID), respectively. These sample size settings aimed to extract background risk factors having a risk ratio of ≥2.5 by using the chi-squared test. Taking into account the proportion of patients meeting the dose reduction criteria in daily clinical settings, it was anticipated that by the time 1000 patients receiving apixaban 2.5 mg BID were registered, 4495 patients receiving 5 mg BID would have been registered.
Accordingly, the final sample size was set to 5500 including at least 1000 patients receiving apixaban 2.5 mg BID.
Registration was possible before the start of treatment with apixaban or within 14 days after the start of treatment. Apixaban doses were selected at the discretion of each treating physician. The follow-up period was 104 weeks for each patient. Data collection was performed at baseline and at 12, 52, and 104 weeks of treatment or at discontinuation of apixaban using case report forms (CRFs) from the participating sites.
This PMS study was conducted as a condition of approval for the use of apixaban in Japanese NVAF patients, and in accordance with the Declaration of Helsinki and the Good Post-marketing Study Practice (GPSP) ordinance of Japan. Approval of the institutional review board of each participating institution and written informed consent were not required because this study was conducted as a regulatory and legal requirement in accordance with the GPSP guidelines. Outcome events for effectiveness analysis included thromboembolic events, such as ischemic stroke, SE, and transient ischemic attack (TIA).
| Assessments and outcomes
| Statistical analysis
Data are expressed as mean ± standard deviation (SD), median, or percentage. The incidence (%) of ADRs was tabulated. The incidence rates (% per year) of major hemorrhage, any hemorrhage, and effectiveness outcomes were also calculated, and cumulative incidence was analyzed using a Kaplan-Meier curve. In the three subgroups categorized by prior anticoagulation status, differences in continuous variables were analyzed using analysis of variance, differences in categorical variables were analyzed using the chisquared test, and incidence rates were tested by the log-rank test.
P < 0.05 were considered statistically significant. Statistical analyses were performed with sas software, version 9.2 (sas Institute Inc., Cary, NC, USA).
| RE SULTS
Of 6455 patients enrolled from September 2013 to August 2014, four patients were excluded from the registration owing to duplicate registration (n = 1), absence of study drug initiation (n = 2), and registration from an institution not participating in this registry (n = 1);
CRFs were not obtained from 79 patients ( Figure 1 ). Additionally, 66
patients were not included in the analysis; therefore, 6306 patients constituted the study group for safety analysis. Of these, 20 patients who were given apixaban for treatment of diseases other than AF were excluded, and the remaining 6286 patients thus constituted the study group for the effectiveness analysis ( Figure 1 ). Four patients had a CrCl value of <15 mL/min, a contraindication of apixaban treatment, but were included in the present analyses. Table 2 .
| Baseline clinical characteristics
Baseline clinical characteristics of the three subgroups are shown in Table 3 . Patients in whom warfarin had been switched to apixaban were older, had lower body weight and CrCl values, and had higher thromboembolic and bleeding risk scores compared with the remaining two subgroups.
| Outcome events
Of 6306 patients included in the safety analysis set, follow-up was Incidence rates of major hemorrhage by baseline HAS-BLED scores are shown in Figure 3 . Common (≥0.5%) ADRs were epistaxis, subcutaneous hemorrhage, and hematuria (Table S1 ). Of 6286 patients included in the effectiveness analysis set, ischemic stroke, SE, and TIA occurred in 89 patients (1.00% per year; Table 5 , Figure 2 ). Of 79 episodes of ischemic stroke, 57% were of cardioembolic origin. Incidence rates of ischemic stroke/SE/TIA by baseline risk scores are shown in Figure 3 .
No outcome events were observed in four patients (79-89 years old; three women; and apixaban 2.5 mg BID in three and 5 mg BID in one) who had baseline CrCl values of <15 mL/min.
As shown in Tables 4 and 5 , incidence rates of outcome events did not differ significantly among the three subgroups divided by prior status of anticoagulation therapy.
| D ISCUSS I ON
This PMS study included more than 6000 patients with NVAF and identified the following major findings. First, 42.7% of the patients received 2.5 mg BID apixaban. Second, incidence rates of major hemorrhage and thromboembolic events were 2.36% per year and 1.00% per year, respectively. No new safety signals were identified. Third, some clinical characteristics differed among the three subgroups based on the status of anticoagulation therapy prior to apixaban treatment, but incidence rates of hemorrhagic and thromboembolic events did not differ among the three subgroups.
TA B L E 2 Reasons for switching from other anticoagulants to apixaban
Reasons for switching from warfarin to apixaban (n = 2038) 
| Comparison with the ARISTOTLE study
A comparison with the apixaban group of the ARISTOTLE study 8 showed that patients in the present study were at a higher hem- thromboembolism compared with the general Japanese population with NVAF.
The hemorrhagic risk of apixaban, dabigatran, and rivaroxaban, compared with warfarin, was assessed in a retrospective claims database study in Japanese NVAF patients using a propensity-matched analysis. 14 Before the propensity matching, patients receiving apixaban were older (mean age, 76.7 vs 72.3-74.4 years) and had reduced renal function (comorbid renal dysfunction, 4.9% vs 2.4%-3.3%) compared with those receiving dabigatran or rivaroxaban. 14 These findings were consistent with the present study in comparison with the PMS studies of rivaroxaban 26 and dabigatran 27 in terms of higher mean age (74.5 vs 73.1 26 and 70.8 years 27 ) and reduced CrCl (62.2 vs 67.7 26 and 72.8 mL/min 27 ) in patients receiving apixaban.
In the present study, 42.7% of the patients received 2.5 mg BID apixaban. This frequency was similar to that in Japanese registration studies (40.4% 28 and 44% 16 ), but lower than that in a Japanese claims database study (60.6% 25 ).
| Switch from other anticoagulants
Patients who switched from warfarin to apixaban were older, and had lower body weight and CrCl values compared with the other two subgroups. Moreover, thromboembolic and bleeding risk scores were higher in this subgroup. Nevertheless, incidence rates of outcome events did not differ significantly among all the subgroups.
In our study, poor INR control was the most common reason for switching from warfarin to apixaban, with the risk score of stroke or hemorrhage being higher in patients who switched from warfarin compared with apixaban initiators (Tables 2 and 3 ). Indeed, results from a nationwide database study indicated that Japanese NVAF patients who continued to receive warfarin had both poor or inadequate INR control and higher stroke risk compared with those who switched from warfarin to NOACs. 29 Approximately 70% of patients who switched from warfarin to apixaban due to uncontrolled INR started apixaban at an INR value of <2.0 as recommended in the Japanese package insert of apixaban. 22 Importantly, the incidence rate of hemorrhagic events did not increase in patients switching from warfarin to apixaban (Table 4) . Thus, it remains crucial for physicians to follow this INR prerequisite in patients who are to switch from warfarin to apixaban. With regard to switching from other NOACs, a number of reasons were reported for doing so in the present study (Table 2) . Medication switching from an index NOAC occurs in one in five patients with NVAF in the United States and is therefore not uncommon 30 ; however, the reasons behind switching have not been well studied, and practical clinical guidelines for switching between NOACs are lacking. Our findings, therefore, provide some insight into the real-world experience in switching between NOACs in Japan.
| Limitations
This study had some limitations. First, the single-cohort design prevented comparisons with warfarin or other NOACs. Second, 37.8% of the patients discontinued apixaban treatment or were lost to follow during the 104-week follow-up period. Discontinuation of periodical visits and transfer to other hospitals/clinics accounted for 51% of these patients for whom the follow-up was discontinued. This rate seemed a little higher, but the clinical status of these patients at the discontinuation of apixaban was determined, yielding a mean follow-up period of 17.4 months. This result was similar to that of a previous Japanese PMS of another NOAC, which was designed to follow the patients for 104 weeks, but yielded a mean follow-up period of approximately 15 months. 31 The shorter follow-up period than designed would have underestimated event rates in the present study as well as in that PMS study. 31 Third, as a result of the inherent limitations of a noninterventional design, this study may not have generated unbiased relative risk estimates or absolute incidence rates. Fourth, since some of the reasons for switching from other anticoagulants to apixaban are subjective, the possibility of selection bias and confounding bias cannot be ruled out. Fifth, possible misclassifications of events cannot be ruled out since events were assessed by treating physicians and were not confirmed by an independent adjudication committee. Sixth, adherence of prescribing apixaban was not evaluated in F I G U R E 2 Cumulative incidence rate of (A) major hemorrhage and (B) ischemic stroke, SE, and TIA. SE, systemic embolism; TIA, transient ischemic attack the present study. Seventh, upon comparison of patient background and incidence rates, safety and effectiveness among the three subgroups categorized by prior anticoagulation therapy, power was not considered for the P value calculation. Finally, changes in apixaban doses were not considered in the course of treatment, and event rates were determined using the baseline apixaban doses. Approximately 900 patients did not meet ≥2 dose reduction criteria but received 2.5 mg BID apixaban, socalled underdose. The association of apixaban doses and dose reduction criteria with outcome events seems clinically relevant, but is not reported herein. This will be reported separately.
| CON CLUS IONS
No new safety signals of apixaban were identified in Japanese NVAF patients. The safety and effectiveness profile for apixaban was consistent with that in the ARISTOTLE study. There was no notable difference in safety or effectiveness event rates among apixaban initiators, patients switched from warfarin, and those switched from other NOACs.
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